{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:57:51Z","timestamp":1773982671861,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00105-015-3656-3","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T07:41:46Z","timestamp":1438328506000},"page":"574-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pemphigus"],"prefix":"10.1007","volume":"66","author":[{"given":"R.","family":"Eming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"key":"3656_CR1","doi-asserted-by":"crossref","unstructured":"Ahmed AR (2001) Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45:679\u2013690","DOI":"10.1067\/mjd.2001.116339"},{"key":"3656_CR2","doi-asserted-by":"crossref","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA et al (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772\u20131779","DOI":"10.1056\/NEJMoa062930"},{"key":"3656_CR3","doi-asserted-by":"crossref","unstructured":"Amagai M, Ikeda S, Shimizu H et al (2009) A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 60:595\u2013603","DOI":"10.1016\/j.jaad.2008.09.052"},{"key":"3656_CR4","doi-asserted-by":"crossref","unstructured":"Amagai M, Komai A, Hashimoto T et al (1999) Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 140:351\u2013357","DOI":"10.1046\/j.1365-2133.1999.02752.x"},{"key":"3656_CR5","doi-asserted-by":"crossref","unstructured":"Amber KT, Staropoli P, Shiman MI et al (2013) Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol 22:699\u2013704","DOI":"10.1111\/exd.12229"},{"key":"3656_CR6","doi-asserted-by":"crossref","unstructured":"Anhalt GJ, Labib RS, Voorhees JJ et al (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189\u20131196","DOI":"10.1056\/NEJM198205203062001"},{"key":"3656_CR7","doi-asserted-by":"crossref","unstructured":"Antoniu S (2014) Epratuzumab for systemic lupus erythematosus. Expert Opin Biol Ther 14:1045\u20131047","DOI":"10.1517\/14712598.2014.915937"},{"key":"3656_CR8","doi-asserted-by":"crossref","unstructured":"Arin MJ, Engert A, Krieg T et al (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620\u2013625","DOI":"10.1111\/j.1365-2133.2005.06651.x"},{"key":"3656_CR9","doi-asserted-by":"crossref","unstructured":"Balighi K, Daneshpazhooh M, Khezri S et al (2013) Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol 52:862\u2013867","DOI":"10.1111\/j.1365-4632.2012.5847.x"},{"key":"3656_CR10","doi-asserted-by":"crossref","unstructured":"Beck LA, Thaci D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130\u2013139","DOI":"10.1056\/NEJMoa1314768"},{"key":"3656_CR11","unstructured":"Borradori L, Lombardi T, Samson J et al (2001) Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137:269\u2013272"},{"key":"3656_CR12","doi-asserted-by":"crossref","unstructured":"Bystryn JC, Rudolph JL (2005) Pemphigus. Lancet 366:61\u201373","DOI":"10.1016\/S0140-6736(05)66829-8"},{"key":"3656_CR13","doi-asserted-by":"crossref","unstructured":"Calabresi PA, Radue EW, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsingremitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545\u2013556","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"3656_CR14","doi-asserted-by":"crossref","unstructured":"Colliou N, Picard D, Caillot F et al (2013) Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 5:175ra130","DOI":"10.1126\/scitranslmed.3005166"},{"key":"3656_CR15","doi-asserted-by":"crossref","unstructured":"Czernik A, Toosi S, Bystryn JC et al (2012) Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 45:111\u2013118","DOI":"10.3109\/08916934.2011.606452"},{"key":"3656_CR16","doi-asserted-by":"crossref","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217\u20131220","DOI":"10.1136\/annrheumdis-2012-202657"},{"key":"3656_CR17","doi-asserted-by":"crossref","unstructured":"Ellebrecht CT, Choi EJ, Allman DM et al (2014) Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol 150:1331\u20131335","DOI":"10.1001\/jamadermatol.2014.1939"},{"key":"3656_CR18","doi-asserted-by":"crossref","unstructured":"Emery P, Burmester GR, Bykerk VP et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19\u201326","DOI":"10.1136\/annrheumdis-2014-206106"},{"key":"3656_CR19","doi-asserted-by":"crossref","unstructured":"Eming R, Hertl M (2006) Immunoadsorption in pemphigus. Autoimmunity 39:609\u2013616","DOI":"10.1080\/08916930600972040"},{"key":"3656_CR20","doi-asserted-by":"crossref","unstructured":"Eming R, Nagel A, Wolff-Franke S et al (2008) Rituximab exerts a dual effect in Pemphigus vulgaris. J Invest Dermatol 128(12):2850\u20132858","DOI":"10.1038\/jid.2008.172"},{"key":"3656_CR21","doi-asserted-by":"crossref","unstructured":"Eming R, Rech J, Barth S et al (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 212:177\u2013187","DOI":"10.1159\/000090659"},{"key":"3656_CR22","doi-asserted-by":"crossref","unstructured":"Faurschou M, Jayne DR (2014) Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med 65:263\u2013278","DOI":"10.1146\/annurev-med-070912-133235"},{"key":"3656_CR23","doi-asserted-by":"crossref","unstructured":"Feliciani C, Toto P, Amerio P et al (2000) In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 114:71\u201377","DOI":"10.1046\/j.1523-1747.2000.00835.x"},{"key":"3656_CR24","doi-asserted-by":"crossref","unstructured":"Feliciani C, Toto P, Wang B et al (2003) Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 12:466\u2013471","DOI":"10.1034\/j.1600-0625.2002.120415.x"},{"key":"3656_CR25","doi-asserted-by":"crossref","unstructured":"Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulators, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930","DOI":"10.1002\/art.30613"},{"key":"3656_CR26","doi-asserted-by":"crossref","unstructured":"Genovese MC, Kinnman N, de La Bourdonnaye G et al (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 63:1793\u20131803","DOI":"10.1002\/art.30373"},{"key":"3656_CR27","doi-asserted-by":"crossref","unstructured":"Ginzler EM, Wax S, Rajeswaran A et al (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14:R33","DOI":"10.1186\/ar3738"},{"key":"3656_CR28","doi-asserted-by":"crossref","unstructured":"Gong Q, Ou Q, Ye S et al (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817\u2013826","DOI":"10.4049\/jimmunol.174.2.817"},{"key":"3656_CR29","doi-asserted-by":"crossref","unstructured":"Hall RP 3rd, Fairley J, Woodley D et al (2015) A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol 172:760\u2013768","DOI":"10.1111\/bjd.13350"},{"key":"3656_CR30","doi-asserted-by":"crossref","unstructured":"Hammers CM, Chen J, Lin C et al (2015) Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol 135:742\u2013749","DOI":"10.1038\/jid.2014.291"},{"key":"3656_CR31","doi-asserted-by":"crossref","unstructured":"Heizmann M, Itin P, Wernli M et al (2001) Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66:142\u2013144","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0"},{"key":"3656_CR32","doi-asserted-by":"crossref","unstructured":"van der Helm LH, Bosman MC, Schuringa JJ et al (2015) Effective trageting of primitive AML CD34+-cells by the second-generation proteasome inhibitor carfilzomib. Br J Haematol doi:10.1111\/bjh.13418","DOI":"10.1111\/bjh.13418"},{"key":"3656_CR33","unstructured":"Hertl M, Eming R (2009) Pemphigus vulgaris. CME Dermatol 4:94\u2013115"},{"key":"3656_CR34","doi-asserted-by":"crossref","unstructured":"Hertl M, Eming R, Borradori L (2007) Rituximab (anti-CD20 monoclonal antibody)\u2013ultimate or first choice in pemphigus? Dermatology 214:275\u2013277","DOI":"10.1159\/000100876"},{"key":"3656_CR35","doi-asserted-by":"crossref","unstructured":"Hertl M, Eming R, Veldman C (2006) T cell control in autoimmune bullous skin disorders. J Clin Invest 116:1159\u20131166","DOI":"10.1172\/JCI28547"},{"key":"3656_CR36","doi-asserted-by":"crossref","unstructured":"Hertl M, Zillikens D, Borradori L et al (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 6:366\u2013373","DOI":"10.1111\/j.1610-0387.2007.06602.x"},{"key":"3656_CR37","doi-asserted-by":"crossref","unstructured":"Hoitsma AJ, Woodle ES, Abramowicz D et al (2011) FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant 26:3802\u20133805","DOI":"10.1093\/ndt\/gfr503"},{"key":"3656_CR38","doi-asserted-by":"crossref","unstructured":"Hueber W, Patel DD, Dryja T et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52\u201372","DOI":"10.1126\/scitranslmed.3001107"},{"key":"3656_CR39","doi-asserted-by":"crossref","unstructured":"Jacobi A, Shuler G, Hertl M (2005) Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 153:448\u2013449","DOI":"10.1111\/j.1365-2133.2005.06744.x"},{"key":"3656_CR40","doi-asserted-by":"crossref","unstructured":"Joly P, Mouquet H, Roujeau JC et al (2007) A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 357:545\u2013552","DOI":"10.1056\/NEJMoa067752"},{"key":"3656_CR41","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Eming R, Behzad M et al (2012) Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges 10:727\u2013732","DOI":"10.1111\/j.1610-0387.2012.07931.x"},{"key":"3656_CR42","doi-asserted-by":"crossref","unstructured":"Kaur K, Kalra S, Kaushal S (2014) Systemic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther 36:1074\u20131086","DOI":"10.1016\/j.clinthera.2014.06.018"},{"key":"3656_CR43","doi-asserted-by":"crossref","unstructured":"Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges 9:844\u2013856","DOI":"10.1111\/j.1610-0387.2011.07793.x"},{"key":"3656_CR44","doi-asserted-by":"crossref","unstructured":"Knier B, Hemmer B, Korn T (2014) Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opin Biol Ther 14:503\u2013513","DOI":"10.1517\/14712598.2014.887676"},{"key":"3656_CR45","doi-asserted-by":"crossref","unstructured":"Kwon EJ, Yamagami J, Nishikawa T et al (2008) Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol 22:1070\u20131075","DOI":"10.1111\/j.1468-3083.2008.02715.x"},{"key":"3656_CR46","doi-asserted-by":"crossref","unstructured":"Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials. N Engl J Med 371:326\u2013338","DOI":"10.1056\/NEJMoa1314258"},{"key":"3656_CR47","doi-asserted-by":"crossref","unstructured":"Li N, Zhao M, Hilario-Vargas J et al (2005) Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440\u20133450","DOI":"10.1172\/JCI24394"},{"key":"3656_CR48","doi-asserted-by":"crossref","unstructured":"L\u00fcftl M, Stauber A, Mainka A et al (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598\u2013605","DOI":"10.1046\/j.1365-2133.2003.05513.x"},{"key":"3656_CR49","doi-asserted-by":"crossref","unstructured":"Lunardon L, Payne AS (2012) Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J Allergy Clin Immunol 130:800\u2013803","DOI":"10.1016\/j.jaci.2012.03.022"},{"key":"3656_CR50","unstructured":"Lunardon L, Payne AS (2012) Rituximab for autoimmune blistering diseases: recent studies, new insights. G Ital Dermatol Venereol 147:269\u2013276"},{"key":"3656_CR51","doi-asserted-by":"crossref","unstructured":"Lunardon L, Tsai KJ, Propert KJ et al (2012) Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 148:1031\u20131036","DOI":"10.1001\/archdermatol.2012.1522"},{"key":"3656_CR52","doi-asserted-by":"crossref","unstructured":"Lutterotti A, Yousef S, Sputtek A et al (2013) Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Trans Med 5:188ra75","DOI":"10.1126\/scitranslmed.3006168"},{"key":"3656_CR53","doi-asserted-by":"crossref","unstructured":"Mariette X, Seror R, Quartuccio L et al (2015) Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 74:526\u2013531","DOI":"10.1136\/annrheumdis-2013-203991"},{"key":"3656_CR54","doi-asserted-by":"crossref","unstructured":"Mease PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27:127\u2013133","DOI":"10.1097\/BOR.0000000000000147"},{"key":"3656_CR55","doi-asserted-by":"crossref","unstructured":"Merrill JT, Burgos-Vargas R, Westhovens R et al (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of twelve-month, multicenter, exploratory phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:3077\u20133087","DOI":"10.1002\/art.27601"},{"key":"3656_CR56","doi-asserted-by":"crossref","unstructured":"Meurer M, Braun-Falco O (1979) Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 100:231\u2013232","DOI":"10.1111\/j.1365-2133.1979.tb05571.x"},{"key":"3656_CR57","doi-asserted-by":"crossref","unstructured":"Nagel A, Hertl M, Eming R (2009) B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 129:289\u2013301","DOI":"10.1038\/jid.2008.192"},{"key":"3656_CR58","doi-asserted-by":"crossref","unstructured":"Nagel A, Podstawa E, Eickmann M et al (2009) Rituximab mediates a strong elevation of B-cellactivating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 129:2202\u20132210","DOI":"10.1038\/jid.2009.27"},{"key":"3656_CR59","doi-asserted-by":"crossref","unstructured":"Narbutt J, Lukamowicz J, Bogaczewicz J et al (2008) Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediatros Inflamm doi:10.1155\/2008\/875394","DOI":"10.1155\/2008\/875394"},{"key":"3656_CR60","doi-asserted-by":"crossref","unstructured":"Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"3656_CR61","doi-asserted-by":"crossref","unstructured":"Nigrovic PA, Mannion M, Prince FH et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63:545\u2013555","DOI":"10.1002\/art.30128"},{"key":"3656_CR62","doi-asserted-by":"crossref","unstructured":"de Paoli FV, Nielsen BD, Rasmussen F et al (2014) Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 43:342\u2013345","DOI":"10.3109\/03009742.2013.812238"},{"key":"3656_CR63","doi-asserted-by":"crossref","unstructured":"Pardo J, Mercader P, Mahiques L et al (2005) Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 153:222\u2013223","DOI":"10.1111\/j.1365-2133.2005.06672.x"},{"key":"3656_CR64","doi-asserted-by":"crossref","unstructured":"Payne AS, Hanakawa Y, Amagai M et al (2004) Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol 16:536\u2013543","DOI":"10.1016\/j.ceb.2004.07.006"},{"key":"3656_CR65","doi-asserted-by":"crossref","unstructured":"Pfutze M, Eming R, Kneisel A et al (2009) Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218:237\u2013245","DOI":"10.1159\/000187431"},{"key":"3656_CR66","doi-asserted-by":"crossref","unstructured":"Rizzo C, Fotino M, Zhang Y et al (2005) Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol 30:535\u2013540","DOI":"10.1111\/j.1365-2230.2005.01836.x"},{"key":"3656_CR67","doi-asserted-by":"crossref","unstructured":"Ruperto N, Brunner HI, Quartier P et al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396\u20132406","DOI":"10.1056\/NEJMoa1205099"},{"key":"3656_CR68","unstructured":"Sardy M, Kasperkiewicz M (2013) Bullous autoimmune disorders in children. Hautarzt 64:447\u2013455"},{"key":"3656_CR69","doi-asserted-by":"crossref","unstructured":"Schmidt E, Klinker E, Opitz A et al (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222\u20131229","DOI":"10.1046\/j.1365-2133.2003.05302.x"},{"key":"3656_CR70","doi-asserted-by":"crossref","unstructured":"Schmidt E, Hennig K, Mengede C et al (2009) Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 132:334\u2013341","DOI":"10.1016\/j.clim.2009.05.007"},{"key":"3656_CR71","doi-asserted-by":"crossref","unstructured":"Seidling V, Hoffmann JH, Enk AH, et al (2013) Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 93:346\u2013349","DOI":"10.2340\/00015555-1471"},{"key":"3656_CR72","doi-asserted-by":"crossref","unstructured":"Shimanovich I, Herzog S, Schmidt E et al (2006) Improved protocol for treatment of pemphigus vulgaris with protein a immunoadsorption. Clin Exp Dermatol 31:768\u2013774","DOI":"10.1111\/j.1365-2230.2006.02220.x"},{"key":"3656_CR73","doi-asserted-by":"crossref","unstructured":"Spindler V, R\u00f6tzer V, Dehner C et al (2013) Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J Clin Invest 123:800\u2013811","DOI":"10.1172\/JCI60139"},{"key":"3656_CR74","doi-asserted-by":"crossref","unstructured":"Steinfeld SD, Youinou P (2006) Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 6:943\u2013949","DOI":"10.1517\/14712598.6.9.943"},{"key":"3656_CR75","doi-asserted-by":"crossref","unstructured":"Stohl W, Merrill JT, McKay JD et al (2013) Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol 40:579\u2013589","DOI":"10.3899\/jrheum.120886"},{"key":"3656_CR76","doi-asserted-by":"crossref","unstructured":"Toosi S, Habib N, Torres G et al (2011) Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus. J Invest Dermatol 131:2327\u20132329","DOI":"10.1038\/jid.2011.184"},{"key":"3656_CR77","doi-asserted-by":"crossref","unstructured":"Veldman C, Hohne A, Dieckmann D et al (2004) Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol 172:6468\u20136475","DOI":"10.4049\/jimmunol.172.10.6468"},{"key":"3656_CR78","doi-asserted-by":"crossref","unstructured":"Wallace DJ, Gordon C, Strand V et al (2013) Efficacy and safety of epratuzumab in patients with moderate\/flaring systemic lupus erythematosus: results of two randomied, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 52:1313\u20131322","DOI":"10.1093\/rheumatology\/ket129"},{"key":"3656_CR79","doi-asserted-by":"crossref","unstructured":"Wenzel S, Ford L, Pearlman D et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455\u20132466","DOI":"10.1056\/NEJMoa1304048"},{"key":"3656_CR80","doi-asserted-by":"crossref","unstructured":"Xing L, Dai Z, Jabbari A et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043\u20131049","DOI":"10.1038\/nm.3645"},{"key":"3656_CR81","doi-asserted-by":"crossref","unstructured":"Yokoyama T, Amagai M (2010) Immune dysregulation of pemphigus in humans and mice. J Dermatol 37:205\u2013213","DOI":"10.1111\/j.1346-8138.2009.00797.x"},{"key":"3656_CR82","doi-asserted-by":"crossref","unstructured":"Zillikens D, Derfler K, Eming R et al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881\u2013887","DOI":"10.1111\/j.1610-0387.2007.06342.x"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-015-3656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-015-3656-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-015-3656-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:40:46Z","timestamp":1558582846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-015-3656-3"}},"subtitle":["Modellerkrankung f\u00fcr zielgerichtete Therapien","Model disease for targeted therapy"],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["3656"],"URL":"https:\/\/doi.org\/10.1007\/s00105-015-3656-3","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}